Duchenne muscular dystrophy (DMD)

DNA
Pharma

Sarepta shares more Elevidys safety data

Eight patients have passed away following treatment with Elevidys, including six unrelated to the gene therapy, Sarepta said.
Angus Liu Aug 18, 2025 11:32am
sarepta building

With $1B in debts due in 2027, Sarepta weighs efficiency measures

Aug 6, 2025 5:44pm
sarepta building

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
An artists impression of DNA The DNA appears to be made up of glowing orbs and appears on a blue background

Roche will continue seeking path forward for Elevidys in EU

Jul 25, 2025 9:55am
pause hold stop delay

Roche halts Elevidys distribution in some countries

Jul 23, 2025 10:56am
Redbrick building with Sarepta name and logo

Sarepta, bowing to FDA's request, pauses shipments of Elevidys

Jul 22, 2025 9:25am